Cochlear reconnects more than 250,000 people to the world of sound in more than 100 countries. Since 1983, Cochlear has grown from its home base in Sydney, Australia to become the world leader in cochlear implants and bone anchored solutions for patients with severe to profound hearing loss. Being the global market leader in implantable hearing solutions, it is our goal continuing to lead the science of hearing by providing the most advanced, life-enhancing technological innovations. To achieve this goal, we invest in cutting edge research and development – around twice in industry average. Almost 15% of our worldwide colleagues are involved in research and development, partnering with the world’s leading researchers and hearing professionals. It’s no wonder we lead worldwide research into new benchmarks of hearing performance. Over the past 15 months we launched three new products – Nucleus® 5, Baha® BP100 and HybridTM – and there are a lot of projects and concepts ahead. In Mechelen, our Cochlear activities consist of production facility, European research and development, EMEA Academy and the Benelux sales and marketing department. The global commercial launch of a new hearing implant prosthesis called Codacs will also be coordinated from Mechelen. Altogether an enthusiastic team of 100 colleagues committed in delivering technology leadership that sets standards in all our products.
: Science and scientific research - Medical Technology
Cochlear Technology Centre
Schaliënhoevedreef 20 I